학술논문
Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine.
Document Type
Article
Author
Patel, Sweta M.; Shaik-Dasthagirisaheb, Yazdani B.; Congdon, Morgan; Young, Rebecca R.; Patel, Mohamed Z.; Mazhani, Tiny; Boiditswe, Sefelani; Leburu, Tirayaone; Lechiile, Kwana; Arscott-Mills, Tonya; Steenhoff, Andrew P.; Feemster, Kristen A.; Shah, Samir S.; Cunningham, Coleen K.; Pelton, Stephen I.; Kelly, Matthew S.
Source
Subject
*PNEUMOCOCCAL vaccines
*VACCINATION status
*DRUG resistance in bacteria
*EPIDEMIOLOGY
*NATURAL immunity
*
*
*
*
Language
ISSN
1932-6203
Abstract
Pneumococcal conjugate vaccines reduce the burden of invasive pneumococcal disease, but the sustained effect of these vaccines can be diminished by an increase in disease caused by non-vaccine serotypes. To describe pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine (PCV-13) in July 2012, we performed molecular serotyping of 268 pneumococcal strains isolated from 221 children between 2012 and 2017. The median (interquartile range) age of the children included in this analysis was 6 (3,12) months. Fifty-nine percent of the children had received at least one dose of PCV-13 and 35% were fully vaccinated with PCV-13. While colonization by vaccine serotypes steadily declined following PCV-13 introduction, 25% of strains isolated more than 3 years after vaccine introduction were PCV-13 serotypes. We also observed an increase in colonization by non-vaccine serotypes 21 and 23B, which have been associated with invasive pneumococcal disease and antibiotic resistance in other settings. [ABSTRACT FROM AUTHOR]